accountDutch biotechnology firm Crucell said on Monday Johnson & Johnson had bought 14.6 million new Crucell shares for 302 million euros ($443.5 million) as part of a flu vaccine development deal. Crucell said the collaboration will...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Crucell Gets J&J Investment Worth $443.5 Million
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account